Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-2581PMID 19240170PMCID PMC2745309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

  2009cited by this paper
• Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment.

  2009cited by this paper
• Head and neck cancer: changing epidemiology, diagnosis, and treatment.

  2008cited by this paper
• EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.

  2008cited by this paper
• Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.

  2008cited by this paper
• Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

  2008cited by this paper
• Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

  2008cited by this paper
• The BCL-2 protein family: opposing activities that mediate cell death

  2008cited by this paper
• Individualized treatment selection in patients with head and neck cancer: do molecular markers meet the challenge?

  2008cited by this paper
• Case-control study of human papillomavirus and oropharyngeal cancer.

  2007cited by this paper
• The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.

  2007cited by this paper
• The Bcl-2 apoptotic switch in cancer development and therapy

  2007cited by this paper
• Inflammatory cell infiltration of tumors: Jekyll or Hyde

  2007cited by this paper
• Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.

  2007cited by this paper
• Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck

  2007cited by this paper
• p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis.

  2006cited by this paper
• Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.

  2006cited by this paper
• Transoral Robotic Surgery (TORS) for Base of Tongue Neoplasms

  2006cited by this paper
• Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.

  2006cited by this paper
• p63 and epithelial biology.

  2006cited by this paper
• p63 and p73: teammates or adversaries?

  2006cited by this paper
• p63 and p73: Life and Death in Squamous Cell Carcinoma

  2006cited by this paper
• DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.

  2005cited by this paper
• Bcl-2 as prognostic factor in head and neck squamous cell carcinoma.

  2005cited by this paper
• Bcl-2 expression predicts radiotherapy failure in laryngeal cancer

  2005cited by this paper
• Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL

  2005cited by this paper
• ΔNp63α Levels Correlate with Clinical Tumor Response to Cisplatin

  2005cited by this paper
• RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.

  2004cited by this paper
• Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer

  2004cited by this paper
• Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.

  2004cited by this paper
• Dominant Negative p63 Isoform Expression in Head and Neck Squamous Cell Carcinoma

  2004cited by this paper
• RACK1 and Stratifin Target ΔNp63α for a Proteasome Degradation in Head and Neck Squamous Cell Carcinoma Cells upon DNA Damage

  2004cited by this paper
• p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

  2003cited by this paper
• Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.

  2003cited by this paper
• Chemosensitivity linked to p73 function.

  2003cited by this paper
• Expression of Bcl‐2 Family Proteins in Advanced Laryngeal Squamous Cell Carcinoma: Correlation With Response to Chemotherapy and Organ Preservation

  2002cited by this paper
• Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays.

  2002cited by this paper
• Predictive Value of P53, BCL-2, and BAX in Advanced Head and Neck Carcinoma

  2002cited by this paper
• Involvement of the hepatocyte growth factor/scatter factor receptor c–met and of Bcl–xL in the resistance of oropharyngeal cancer to ionizing radiation

  2001cited by this paper
• Prognostic value of the expression of p53 and bcl-2 in patients with laryngeal carcinoma

  2001cited by this paper
• Genetic imbalances with impact on survival in head and neck cancer patients.

  2000cited by this paper
• Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma

  2000cited by this paper
• The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

  1999cited by this paper
• Expression von Zellzykluskomponenten in fortgeschrittenen Kopf-Hals-Karzinomen Bedeutung für die Prognose nach primärer akzelerierter Radiochemotherapie

  1999cited by this paper
• [Prognostic significance of cell-cycle regulatory proteins for outcome after primary radiochemotherapy in patients with advanced head and neck cancer].

  1999cited by this paper
• Bcl‐xL and Bcl‐2 expression in squamous cell carcinoma of the head and neck

  1999cited by this paper
• Spontaneous apoptosis in laryngeal squamous cell carcinoma is independent of bcl‐2 and bax protein expression

  1999cited by this paper
• p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.

  1998cited by this paper
• Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma.

  1996cited by this paper
• Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy.

  1996cited by this paper
• bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy.

  1996cited by this paper
• Larynx preservation after initial non-cisplatin containing combination chemotherapy plus radiotherapy, as opposed to surgical intervention with or without radiotherapy in previously untreated advanced head and neck cancer: final analysis after 12 years follow-up

  1993cited by this paper
• Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer.

  1987cited by this paper
• Bony meatus homografts

  1972cited by this paper

• Tetrahydroberberine Targets the bcl-2 Promoter G-Quadruplex to Trigger Mitochondrial Apoptosis and Inhibit Nasopharyngeal Carcinoma Progression.

  2026cites this paper
• BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting

  2026cites this paper
• Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy.

  2025cites this paper
• Inhibition of platin-induced BCL2 increase overcomes chemoresistance in squamous cell carcinoma of the head and neck through resensitization to cell death

  2025cites this paper
• BRD9 inhibition as potential treatment option for testicular germ cell tumors.

  2025cites this paper
• SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer

  2025cites this paper
• The microRNA-6510 as a potential tumor suppressor in head and neck cancer

  2025cites this paper
• The pan-BH-3 mimetic, obatoclax, synergistically enhances cisplatin-induced apoptosis in oral squamous cell carcinoma through a mechanism that involves degradation of the pro-survival protein Mcl-1.

  2025cites this paper
• Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck.

  2024cites this paper
• Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.

  2024cites this paper
• Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer

  2024cites this paper
• Comprehensive review of Bcl‐2 family proteins in cancer apoptosis: Therapeutic strategies and promising updates of natural bioactive compounds and small molecules

  2024cites this paper
• Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer

  2024cites this paper
• Groenlandicine enhances cisplatin sensitivity in cisplatin-resistant osteosarcoma cells through the BAX/Bcl-2/Caspase-9/Caspase-3 pathway

  2024cites this paper
• Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.

  2024cites this paper
• SETD8, a frequently mutated gene in cervical cancer, enhances cisplatin sensitivity by impairing DNA repair

  2023cites this paper
• Correlation of Bcl-2 Expression with Prognosis and Survival in Patients with Head and Neck Cancer: A Systematic Review and Meta-Analysis.

  2023cites this paper
• Genetic polymorphisms in genes regulating cell death and prognosis of patients with rectal cancer receiving postoperative chemoradiotherapy

  2023cites this paper
• Association between Cone-Beam Computed Tomography and Histological and Immunohistochemical Features in Periapical Lesions Correlated with Thickened Maxillary Sinus Mucosa

  2021influential citation
• RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction.

  2021cites this paper
• Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

  2021cites this paper
• Mitochondria: The metabolic switch of cellular oncogenic transformation.

  2021cites this paper
• Targeting Bcl-2 for cancer therapy.

  2021cites this paper
• Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis

  2021cites this paper
• ETIOLOGY AND PATHOGENESIS OF HYPOPHARYNX CANCER: GENETIC AND IMMUNOLOGICAL FACTORS OF DEVELOPMENT. Review

  2021cites this paper
• In Response to Regarding: Apoptosis Signaling Molecules as Treatment Targets in Head and Neck Squamous Carcinoma

  2020cites this paper
• Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells

  2020cites this paper
• Links between cancer metabolism and cisplatin resistance.

  2020cites this paper
• Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma

  2020cites this paper
• Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer

  2020cites this paper
• Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl‐2 in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2020cites this paper
• Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives

  2020cites this paper
• Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1

  2019cites this paper
• The association of Bcl-xL and p53 expression with survival outcomes in oropharyngeal cancer

  2019cites this paper
• Ru(II)-Based Amino Acid Complexes Show Promise for Leukemia Treatment: Cytotoxicity and Some Light on their Mechanism of Action

  2019cites this paper
• Cu(ii) phenanthroline-phenazine complexes dysregulate mitochondrial function and stimulate apoptosis.

  2019cites this paper
• Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations.

  2019cites this paper
• NRAGE confers poor prognosis and promotes proliferation, invasion, and chemoresistance in gastric cancer.

  2018cites this paper
• Contemporary Oral Oncology: Diagnosis and Management

  2018cites this paper
• Identification and characterization of glycobiomarkers in bladder cancer stem cells

  2018cites this paper
• Potential Role of ASC, a Proapoptotic Protein, for Determining the Cisplatin Susceptibility of Lung Cancer Cells.

  2018cites this paper
• Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines

  2018cites this paper
• 53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.

  2018cites this paper
• Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes.

  2018cites this paper
• ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.

  2018cites this paper
• CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer

  2017cites this paper
• ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer

  2017cites this paper
• [50th anniversary of cisplatin].

  2017cites this paper
• Biological Basis of Treatment Failure

  2017cites this paper
• Selective Targeting of Cancer Cells by Oxidative Vulnerabilities with Novel Curcumin Analogs

  2017cites this paper
• Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells

  2016cites this paper
• BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells

  2016cites this paper
• Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

  2016cites this paper
• The Role Of Oxidative Stress In The Establishment Of Resistance To Cisplatin In Epithelial Ovarian Cancer Cells

  2016cites this paper
• Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation.

  2016cites this paper
• HNSCC Biomarkers Derived from Key Processes of Cancerogenesis

  2016cites this paper
• Asplatin enhances drug efficacy by altering the cellular response.

  2016cites this paper
• Epidermal Growth Factor Receptor (EGFR) and Keratin 5 (K5): Versatile Keyplayers Defining Prognostic and Therapeutic Sub-classes of Head and Neck Squamous Cell Carcinomas.

  2016cites this paper
• ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics.

  2015cites this paper
• The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.

  2015cites this paper
• Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells

  2015cites this paper
• DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

  2015cites this paper
• AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.

  2015cites this paper
• Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features

  2015cites this paper
• Biomarkers for Individualized Oral Cancer Therapy

  2015cites this paper
• Inhibition des protéines anti-apoptotiques de la famille Bcl-2 par l'ABT-737 : intérêt pour le traitement des cancers des voies aérodigestives supérieures

  2015cites this paper
• A Novel Platinum-Maurocalcine Conjugate Induces Apoptosis of Human Glioblastoma Cells by Acting through the ROS-ERK/AKT-p53 Pathway.

  2015cites this paper
• Heat Shock Response Associated with Hepatocarcinogenesis in a Murine Model of Hereditary Tyrosinemia Type I

  2014cites this paper
• A novel selenadiazole derivative induces apoptosis in human glioma cells by dephosphorylation of AKT.

  2014cites this paper
• MCL-1 dependency of cisplatin-resistant cancer cells.

  2014cites this paper
• Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy

  2014cites this paper
• Designing biomarker studies for head and neck cancer

  2014cites this paper
• Bcl-2 Family Gene Expression in Oropharyngeal Squamous Cell Carcinoma

  2014cites this paper
• Glyco-profiling of bladder cancer stem cells based on chemotherapy sorting approach

  2014cites this paper
• SERPINB2 down‐regulation contributes to chemoresistance in head and neck cancer

  2014cites this paper
• miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1

  2014cites this paper
• p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.

  2014cites this paper
• Systems biology of cisplatin resistance: past, present and future

  2014cites this paper
• MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer

  2014cites this paper
• Ethno medicinal, phytochemical and pharmacological aspects of solanum incanum (lin.)

  2014cites this paper
• Part of the Special Issue: Metabolism 2014 - Alterations of metabolic pathways as therapeutic targets MCL-1 dependency of cisplatin-resistant cancer cells

  2014cites this paper
• Synergistic induction of apoptosis by methylseleninic acid and cisplatin, the role of ROS-ERK/AKT-p53 pathway.

  2014cites this paper
• Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy

  2013cites this paper
• RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance

  2013cites this paper
• Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

  2013cites this paper
• Personalized Management of Head & Neck Cancer

  2013cites this paper
• Targeting the Bcl-2 family for cancer therapy

  2013cites this paper
• Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma.

  2013cites this paper
• CpG oligodeoxynucleotides enhance chemosensitivity of 5-fluorouracil in HepG2 human hepatoma cells via downregulation of the antiapoptotic factors survivin and livin

  2013cites this paper
• Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: Systematic review and meta‐analysis

  2013cites this paper
• Zerumbone induces apoptosis in human renal cell carcinoma via Gli-1/Bcl-2 pathway.

  2013cites this paper
• Prognostic biomarkers in squamous cell carcinoma of the head and neck

  2013cites this paper
• Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment.

  2013cites this paper
• Mitochondrial fusion: a mechanism of cisplatin-induced resistance in neuroblastoma cells?

  2013cites this paper
• Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.

  2013cites this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF EPSTEIN BARR VIRUS ANTIGEN LATENT MEMBRANE PROTEIN-1 AND BCL-2 IN CLASSICAL HODGKIN LYMPHOMA

  2012cites this paper
• Inhibition of the JAK-STAT3 Signaling Pathway by Ganoderic Acid A Enhances Chemosensitivity of HepG2 Cells to Cisplatin

  2012cites this paper
• Ki-67 expression predicts radiotherapy failure in early glottic cancer.

  2012cites this paper
• Molecular mechanisms of cisplatin resistance

  2012influential citation
• Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.

  2012cites this paper